JSPR.NASDAQJasper Therapeutics, INC
Form 4: Jasper Therapeutics Director Acquires Stock Options
Sentiment:
SEC Form 4
Director Thomas G. Wiggans acquired 7,500 stock options in Jasper Therapeutics, Inc. on June 6, 2024.
Summary
- On June 6, 2024, Thomas G. Wiggans, a director of Jasper Therapeutics, Inc., acquired 7,500 stock options.
- The exercise price of these options is $25.41.
- The options become exercisable on June 6, 2025, and expire on June 6, 2034.
- Following the transaction, Wiggans directly owns 7,500 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the stock option acquisition. |
| 06/06/2025 | Date the stock options become exercisable. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.